---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-25-000074"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T18:59:13.014462+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xencor Q2 2025 revenue $43.6M, net loss $30.8M; Incyte milestone $25M

## Summary
- Revenue $43.6M (up from $23.9M Q2 2024); net loss $30.8M ($0.41/share) vs $67.3M ($1.09) prior year.
- Cash and securities $663.8M (Dec 2024: $706.7M); guidance for year-end $555-585M, runway into 2028.
- Earned $25M regulatory milestone from Incyte for Monjuvi FDA approval in follicular lymphoma.
- Initiated Phase 2b XENITH-UC study of XmAb942 in ulcerative colitis; plans to present XmAb819 data in Q4 2025.
- Appointed Raymond Deshaies, Ph.D., to board of directors; he previously led global research at Amgen.

## SEC filing metadata
- accession: 0001326732-25-000074
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000074/0001326732-25-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000074/xncr-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-25-000074
- JSON: https://secwatch.observer/filing/0001326732-25-000074.json
- Plain text: https://secwatch.observer/filing/0001326732-25-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.